Trial Profile
A pivotal phase III study of PD-protec® in patients suffering from end-stage renal disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Alanylglutamine (Primary)
- Indications Peritonitis
- Focus Registrational; Therapeutic Use
- Sponsors Zytoprotec
- 19 Dec 2017 New trial record